Ximelagatran/melagatran. Perspectives for new oral antithrombin drugs;Ximelagatran/melagatran l'avenir des nouveaux médicaments antithrombine oraux

Journal des Maladies Vasculaires

Volumn 29, Issue 2, 2004, Pages 61-62

  Samama, M M ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; MELAGATRAN; WARFARIN; XIMELAGATRAN;

BLEEDING; BLOOD CLOTTING; EDITORIAL; FRANCE; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; INCIDENCE; RISK ASSESSMENT;

EID: 3042583674     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0398-0499(04)96716-9     Document Type: Editorial

References (8)

1. ERIKSSON BI, BERGQVIST D, KALEBO P, et al. Melagatran for Thrombin inhibition in Orthopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet, 2002; 360: 1441-7.
2. ERIKSSON BI, AGNELLI G, COHEN AT, et al. METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost, 2003; 89: 288-96.
3. ERIKSSON BI, AGNELLI G, COHEN AT, et al. The EXPRESS Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost, 2003; 1: 2490-6.
4. ERIKSSON H. WAHLANDER K, GUSTAFSSON D, et al. for the THRIVE Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis. THRIVE 1. J Thromb Haemost, 2003; 1: 41-7.
5. SCHULMAN S, WAHLANDER K, LUNDSTROM T, et al. THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med, 2003; 349: 1713-21.
6. PETERSEN P, GRIND M, ADLER J. SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with non valvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol, 2003; 41: 1445-51.
7. OLSSON SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet, 2003; 362: 1691-8.
8. HALPERIN JL. Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with non valvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J, 2003; 146: 431-8.